摘要
目的 :探讨三阴性乳腺癌新辅助化疗的疗效以及与预后相关的因素。方法 :回顾性分析2006年1月—2008年12月接受新辅助化疗的三阴性乳腺癌患者的临床特征、新辅助化疗的疗效以及与预后相关的因素。结果 :80例三阴性乳腺癌患者接受新辅助化疗,临床完全缓解率为46.25%(37/80),病理完全缓解率(pathological complete response,pCR)为38.75%(31/80)。未获得pCR(non-pCR)患者的N分期较高、临床分期较晚以及应用不含蒽环类的化疗方案。pCR患者的5年无病生存率和总生存率分别为80.65%和93.55%,non-PCR患者的5年无病生存率和总生存率分别为53.06%和65.34%;pCR与non-pCR患者的5年无病生存率和总生存率的差异均有统计学意义(P=0.008,P=0.004)。多因素分析显示,新辅助化疗后pCR是影响三阴性乳腺癌患者无病生存和总生存率的独立预后因素(P<0.05)。结论 :三阴性乳腺癌患者对新辅助化疗较为敏感,含蒽环类的化疗方案更易获得pCR,而pCR患者的预后明显优于non-pCR患者。
Objective: To investigate the response to neoadjuvant chemotherapy in patients with triple- negative breast cancer (TNBC) and the prognostic factors. Methods: The clinicopathologic features, the response to neoadjuvant chemotherapy, the disease-free survival and overall survival, and the prognostic factors were retrospectively analyzed in 80 hospitalized patinets with TNBC receiving neoadjuvant chemotherapy between January 2006 and December 2008. Results: Of the 80 TNBC patients receiving neoadjuvant chemotherapy, the clinical complete response (cCR) and the pathological complete response (pCR) were 46.25% (37/80) and 38.75% (31/80), respectively. The patients with non-pCR (61.25%) had a higher stage of lymph node and an advanced clinical stage before chemotherapy, and they were more likely to receive non-anthracyclin-based neoadjuvant regimens. The 5-year disease-free survival rates of pCR and non-pCR patients were 80.65% and 53.06%, respectively (P = 0.008), and the 5-year overall survival rates of pCR and non-pCR patients were 93.55% and 65.34%, respectively (P = 0.004). Multivariate analysis showed that pCR was an independent prognostic factor. Conclusion: Patients with TNBC were more sensitive to neoadjvant chemotherapy. The regimens including anthracycline is helpful to achieve pCR. TNBC patients with pCR may have a better prognosis than non-pCR.
出处
《肿瘤》
CAS
CSCD
北大核心
2014年第5期454-457,463,共5页
Tumor
基金
天津市科技计划项目(编号:12ZCDZSY16200)
关键词
乳腺肿瘤
三阴性
新辅助化疗
病理完全缓解
预后
Breast neoplasms
Triple-negative
Neoadjuvant chemotherapy
Pathological complete response
Prognosis